Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/29/2018
Start Date:July 27, 2016
End Date:December 30, 2019
Contact:Toll Free Number
Email:Trialsites@merck.com
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)

The study will consist of two parts. In Part 1, the safety of pembrolizumab (MK-3475) in
combination with one of three different chemotherapies will be assessed in the treatment of
locally recurrent inoperable or metastatic triple negative breast cancer (TNBC), which has
not been previously treated with chemotherapy. In Part 2, the safety and efficacy of
pembrolizumab plus chemotherapy will be assessed compared to the safety and efficacy of
placebo plus chemotherapy in the treatment of locally recurrent inoperable or metastatic
TNBC, which has not been previously treated with chemotherapy.

The primary hypotheses are that the combination of pembrolizumab and chemotherapy prolongs
Progression-Free Survival (PFS) compared to placebo and chemotherapy in all participants and
in participants with programmed cell death ligand 1 (PD-L1) positive tumors, and prolongs
Overall Survival (OS) compared to placebo and chemotherapy in all participants and in
participants with PD-L1 positive tumors.


Inclusion Criteria:

- Has locally recurrent inoperable breast cancer not previously treated with
chemotherapy and which cannot be treated with curative intent OR has metastatic breast
cancer not previously treated with chemotherapy.

- Has centrally confirmed TNBC, as defined by the most recent American Society of
Clinical Oncology/college of American Pathologists (ASCO/CAP) guidelines.

- Has completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months
elapsed between the completion of treatment with curative intent (e.g., date of
primary breast tumor surgery or date of last adjuvant chemotherapy administration,
whichever occurred last) and first documented local or distant disease recurrence.

- Has been treated with (neo)adjuvant anthracycline, if they received systemic treatment
in the (neo)adjuvant setting, unless anthracycline was contraindicated or not
considered the best treatment option for the participant in the opinion of the
treating physician.

- Has measurable disease based on Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST 1.1) as determined by local radiology review.

- Has provided recently or newly obtained core or excisional biopsy from a locally
recurrent inoperable or metastatic tumor lesion for central determination of TNBC
status and PD-L1 expression, unless contraindicated due to site inaccessibility and/or
participant safety concerns.

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as
assessed within 10 days prior to the start of study drug.

- Has a life expectancy ≥12 weeks from randomization.

- Demonstrates adequate organ function, within 10 days prior to the start of study drug.

- Female participants of childbearing potential must be willing to use an adequate
method of contraception for the course of the study through 120 days (or longer as
specified by local institutional guidelines) after the last dose of study drug.

- Male participants of childbearing potential must agree to use an adequate method of
contraception starting with the first dose of study drug through 120 days (or longer
as specified by local institutional guidelines) after the last dose of study drug.

Exclusion Criteria:

- Is currently participating in a clinical study and receiving an investigational agent
and/or using an investigational device, or has participated in a clinical study and
received an investigational agent and/or used an investigational device within 4 weeks
prior to randomization.

- Has not recovered (e.g., to ≤ Grade 1 or to baseline) from AEs due to a previously
administered therapy.

- Has neuropathy ≥ Grade 2.

- Has an active autoimmune disease that has required systemic treatment in the past 2
years (e.g., with use of disease modifying agents, corticosteroids, or
immunosuppressive drugs).

- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
other form of immunosuppressive therapy within 7 days prior to randomization.

- Has a known additional malignancy that progressed or required active treatment within
the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell
carcinoma of the skin that has undergone potentially curative therapy, and in situ
cervical cancer.

- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Participants with previously treated brain metastases may participate
provided they have stable brain metastases and did not receive chemotherapy for
metastatic breast cancer.

- Has history of (non-infectious) pneumonitis that required steroids or current
pneumonitis.

- Has active, or a history of, interstitial lung disease.

- Has a known history of active tuberculosis (TB).

- Has an active infection requiring systemic therapy.

- Has a history of Class II-IV congestive heart failure or myocardial infarction within
6 months of randomization.

- Has a known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the study.

- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
(or longer as specified by local institutional guidelines) after the last dose of
study drug.

- Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1),
anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T
cell receptor (such as cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40,
CD137) or has previously participated in Merck pembrolizumab (MK-3475) clinical
studies.

- Has a known history of human immunodeficiency virus (HIV).

- Has known active hepatitis B or hepatitis C.

- Has received a live vaccine within 30 days prior to randomization.

- Has a known history of hypersensitivity or allergy to pembrolizumab and any of its
components and/or to any of the study chemotherapies (e.g., nab-paclitaxel,
paclitaxel, gemcitabine, or carboplatin) and any of their components.

- Is receiving any medication prohibited in combination with study chemotherapies as
described in the respective product labels, unless medication was stopped within 7
days prior to randomization.
We found this trial at
50
sites
1309 W 17th Street
Sioux Falls, South Dakota 57104
(605) 328-8000
Phone: 605-328-8000
Sanford Cancer Center-Oncology Clinic Sanford Health is an integrated health system headquartered in the Dakotas...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
1600 Divisadero Street
San Francisco, California 94115
888.689.8273
Phone: 415-353-7288
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Albany, New York 12208
Phone: 518-525-6418
?
mi
from
Albany, NY
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Phone: 610-314-4161
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Phone: 404-778-3969
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Aurora, Colorado 80045
Phone: 720-848-0719
?
mi
from
Aurora, CO
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Phone: 443-849-3123
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Berazategui, Buenos Aires
Phone: +541142262013
?
mi
from
Berazategui,
Click here to add this to my saved trials
Billings, Montana 59102
Phone: 406-238-6290
?
mi
from
Billings, MT
Click here to add this to my saved trials
Boston, Massachusetts 02118
Phone: 617-638-7017
?
mi
from
Boston, MA
Click here to add this to my saved trials
Burbank, California 91505
Phone: 818-748-4797
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Charleston, South Carolina 29403
?
mi
from
Charleston, SC
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
Phone: 773-834-9774
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1801 West Taylor, Suite 1E
Chicago, Illinois 60612
312.355.1625
Phone: 312-355-0496
University of Illinois Cancer Center The University of Illinois Cancer Center is dedicated to reducing...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
Phone: 513-584-0238
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Deerfield Beach, Florida 33442
Phone: 305-270-3467
?
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Detroit, Michigan 48201
Phone: 313-576-9382
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Detroit, Michigan 48202
Phone: 313-916-1784
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Elk Grove Village, Illinois 60007
Phone: 847-640-3116
?
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
350 Engle St
Englewood, New Jersey 07631
(201) 894-3000
Phone: 201-568-5250
Englewood Hospital and Medical Center Englewood Hospital was incorporated in 1888 as a non-profit, non-sectarian...
?
mi
from
Englewood, NJ
Click here to add this to my saved trials
Evanston, Illinois 60201
Phone: 847-570-2109
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Fargo, North Dakota 58122
Phone: 701-234-2000
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Fullerton, California 92835
Phone: 714-979-4101
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
Greenville, South Carolina 29607
Phone: 864-449-0444
?
mi
from
Greenville, SC
Click here to add this to my saved trials
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Loma Linda, California 92354
Phone: 909-558-4050
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Phone: 323-865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40207
Phone: 502-899-6147
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Macon, Georgia 31201
Phone: 478-743-7068
?
mi
from
Macon, GA
Click here to add this to my saved trials
?
mi
from
Metairie, LA
Click here to add this to my saved trials
Midlothian, Virginia 23114
Phone: 804-893-8663
?
mi
from
Midlothian, VA
Click here to add this to my saved trials
800 E 28th St
Minneapolis, Minnesota 55407
(612) 863-4000
Phone: 612-863-3929
Abbott Northwestern Hospital Our hospital has a long and proud history as a health care...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Monterey, California 93940
Phone: 831-375-4105
?
mi
from
Monterey, CA
Click here to add this to my saved trials
Munster, Indiana 46321
Phone: 219-836-6875
?
mi
from
Munster, IN
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Phone: 732-235-6789
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Newport Beach, California 92663
Phone: 323-865-3000
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Nyack, New York 10960
Phone: 845-362-1750
?
mi
from
Nyack, NY
Click here to add this to my saved trials
Palm Springs, California 92262
Phone: 760-416-4736
?
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Park Ridge, Illinois 60068
Phone: 847-410-0658
?
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Raleigh, North Carolina 27607
Phone: 919-784-7209
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
Richmond, Virginia 23298
Phone: 804-628-6435
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Salt Lake City, Utah 84106
Phone: 801-281-6864
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94115
Phone: 415-668-0160
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Scarborough, Maine 04074
Phone: 207-396-7600
?
mi
from
Scarborough, ME
Click here to add this to my saved trials
Skokie, Illinois 60077
Phone: 224-534-7580
?
mi
from
Skokie, IL
Click here to add this to my saved trials
Summit, New Jersey 07901
Phone: 908-608-0078
?
mi
from
Summit, NJ
Click here to add this to my saved trials
Tacoma, Washington 98405
Phone: 253-428-8750
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tulsa, Oklahoma 74146
Phone: 918-505-3200
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Whittier, California 90603
Phone: 562-693-4477
?
mi
from
Whittier, CA
Click here to add this to my saved trials
Wynnewood, Pennsylvania 19096
Phone: 484-476-2649
?
mi
from
Wynnewood, PA
Click here to add this to my saved trials